Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism

Cites (358)

Items 201–358 of 358

1. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism
   K Hokari, Toshiro Sugiyama, Mototsugu Kato et al. · 2001 · Alimentary Pharmacology & Therapeutics
2. Genetic polymorphism of (S)‐mephenytoin 4′‐hydroxylation in populations of African descent
   Xie, Kim, Stein, Wilkinson, Wood · 1999 · British Journal of Clinical Pharmacology
3. Effects of felbamate on the pharmacokinetics of phenobarbital
   Pascale Reidenberg, Paul Glue, Christopher R. Banfield et al. · 1995 · Clinical Pharmacology & Therapeutics
4. Meta-analysis of phenotype and genotype of NAT2 deficiency in Chinese populations
   Hong‐Guang Xie, Zhenhua Xu, Dongsheng Ouyang · 1997 · Pharmacogenetics
5. High frequencies of CYP2C19 mutations and poor metabolism of proguanil in Vanuatu
   Akira Kaneko, Osamu Kaneko, George K. Taleo, Anders Björkman, Takatoshi Kobayakawa · 1997 · The Lancet
6. Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide*
   U. Jeppesen, Birgitte Buur Rasmussen, Kim Brøsen · 1997 · Clinical Pharmacology & Therapeutics
7. Lack of low Km diazepam N-demethylase in livers of poor metabolizers for S-mephenytoin 4'-hydroxylation
   Toshio Yasumori, Qinghua Li, Yasushi Yamazoe · 1994 · Pharmacogenetics
8. Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: Interethnic differences in comparison with white subjects
   Yuan Zhang, Jesús Reviriego, Ya‐Qing Lou · 1990 · Clinical Pharmacology & Therapeutics
9. Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin*
   Chin B. Eap, Theodor W. Guentert, Martina Schäublin-Loidl · 1996 · Clinical Pharmacology & Therapeutics
10. Extent of Urinary Excretion of p-Hydroxyphenytoin in Healthy Subjects Given Phenytoin
    RONALD G. DICKINSON, Wayne D Hooper, Marc C. Patterson · 1985 · Therapeutic Drug Monitoring
11. Polymorphism in hydroxylation of mephenytoin and hexobarbital stereoisomers in relation to hepatic P-450 human-2
    Toshio Yasumori, Norie Murayama, Yasushi Yamazoe · 1990 · Clinical Pharmacology & Therapeutics
12. Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians*
    Erik Skjelbo, Theonest K. Mutabingwa, Ib Christian Bygbjerg · 1996 · Clinical Pharmacology & Therapeutics
13. Role of cytochrome P450 in estradiol metabolism in vitro.
    Zeneng Cheng, Yan Shu, Zhaoqian Liu, Liansheng Wang, Dongsheng Ouyang, Hong-Hao Zhou · 2001 · PubMed
14. Polymorphic drug metabolism.
    Mary V. Relling · 1989 · PubMed
15. Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers.
    Nobuo Aoyama, Yusuke Tanigawara, Tomoko Kita · 1999 · PubMed
16. The induction effect of rifampicin on activity of mephenytoin 4′‐hydroxylase related to M1 mutation of CYP2C19 and gene dose
    Hua‐Jun Feng, Song‐Lin Huang, Wei Wang, Hong‐Hao Zhou · 1998 · British Journal of Clinical Pharmacology
17. Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population
    Sigal Sviri, Shoshi Shpizen, E LEITERSDORF · 1999 · Clinical Pharmacology & Therapeutics
18. Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevity
    Lise Bathum, Karen Andersen‐Ranberg, Jesper L. Boldsen · 1998 · European Journal of Clinical Pharmacology
19. Cytochrome P450 Enzymes
    Anne Tamborski Harvey, Sheldon Preskorn · 1996 · Journal of Clinical Psychopharmacology
20. CYP2D6 and CYP2C19 genotypes in an elderly Swedish population
    Hiroshi Yamada, Marja­‐Liisa Dahl, L. Lannfelt · 1998 · European Journal of Clinical Pharmacology
21. Pharmacokinetics of [14C]Omeprazole in Patients with Liver Cirrhosis
    Tommy Andersson, Rolf Olsson, Carl Gunnar Regårdh · 1993 · Clinical Pharmacokinetics
22. Stereoselective metabolism and disposition of the enantiomers of mephenytoin during chronic oral administration of the racemic drug in man.
    Adrian Kupfer, Paul V Desmond, S. Schenker · 1982 · Journal of Pharmacology and Experimental Therapeutics
23. Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole*
    Yoseph Caraco, Grant R. Wilkinson, Alastair J. J. Wood · 1996 · Clinical Pharmacology & Therapeutics
24. Determination of CYP2C19 phenotype in black Americans with omeprazole: Correlation with genotype*
    Jacqueline S. Marinac, John Dikran Balian, John W. Foxworth · 1996 · Clinical Pharmacology & Therapeutics
25. Selective Serotonin Reuptake Inhibitors and Tricyclic Antidepressants in Combination
    David M. Taylor · 1995 · The British Journal of Psychiatry
26. Warfarin‐Fluoxetine and Diazepam‐Fluoxetine Interaction
    Larry A. Dent, Marv W. Orrock · 1997 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
27. In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes.
    Mary E. Barecki, Christopher N. Casciano, William W. Johnson · 2001 · PubMed
28. Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors
    Olav Spigset, Karin Hedenmalm, M L Dahl · 1997 · Acta Psychiatrica Scandinavica
29. Relationship of In Vitro Data on Drug Metabolism to In Vivo Pharmacokinetics and Drug Interactions
    Jürgen Schmider, David J. Greenblatt, Lisa Lvon Moltke · 1996 · Journal of Clinical Psychopharmacology
30. Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects
    Zhaoqian Liu, Zeneng Cheng, Song‐Lin Huang · 2001 · British Journal of Clinical Pharmacology
31. Flunitrazepam metabolism by cytochrome P450S 2C19 and 3A4.
    Tansel Kilicarslan, Robert L. Haining, Allan E. Rettie · 2001 · PubMed
32. Pharmacokinetics of various single intravenous and oral doses of omeprazole
    TB Andersson, Christer Cederberg, C. G. Reg�rdh, I. Sk�nberg · 1990 · European Journal of Clinical Pharmacology
33. Interaction studies with moclobemide
    Robert Zimmer, Ronald Gieschke, R. Fischbach · 1990 · Acta Psychiatrica Scandinavica
34. Scleroderma is associated with differences in individual routes of drug metabolism: A study with dapsone, debrisoquin, and mephenytoin
    David G. May, Carol M. Black, Nancy J. Olsen, Mary Ellen Csuka, Simpson Bobo Tanner, Lisa Bellino, James A Porter, Grant R. Wilkinson, Robert A. Branch · 1990 · Clinical Pharmacology & Therapeutics
35. Steady State Plasma Levels of the Enantiomers of Trimipramine and of Its Metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-Phenotyped Patients
    Chin B. Eap, Stefan Bender, Markus Gastpar · 2000 · Therapeutic Drug Monitoring
36. Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population
    Janelle M. Hoskins, Gillian M. Shenfield, Annette S. Gross · 1998 · British Journal of Clinical Pharmacology
37. Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline
    Karin Dilger, Zhichang Zheng, Ulrich E. Klotz · 1999 · British Journal of Clinical Pharmacology
38. Lack of pharmacokinetic interaction of pantoprazole with diazepam in man
    Roland Gugler, M. HARTMANN, J. RUDI · 1996 · British Journal of Clinical Pharmacology
39. Effect of Omeprazole on the Metabolism of Cilostazol
    Ajit Suri, Steven L. Bramer · 1999 · Clinical Pharmacokinetics
40. The Role of CYP2C19 in the Metabolism of (+/–) Bufuralol, the Prototypic Substrate of CYP2D6
    Dayna C. Mankowski · 1999 · Drug Metabolism and Disposition
41. Effects of genetic defects in the CYP2C19 gene on the N‐demethylation of imipramine, and clinical outcome of imipramine therapy
    Shigeru Morinobu, Takeshi Tanaka, Shinobu Kawakatsu, Shiro Totsuka, Eriko Koyama, KAN CHIBA, Takashi Ishizaki, Takahiro Kubota · 1997 · Psychiatry and Clinical Neurosciences
42. Formation of meprobamate from carisoprodol is catalysed byCYP2C19
    P Dal??n, Gunnar Alván, Monique Wakelkamp · 1996 · Pharmacogenetics
43. Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro
    Birgitte Buur Rasmussen, Torben Leo Nielsen, Kim Brøsen · 1998 · European Journal of Clinical Pharmacology
44. Cimetidine interaction with imipramine and nortriptyline
    Stephan A. Henauer, Leo E. Hollister · 1984 · Clinical Pharmacology & Therapeutics
45. Genetic polymorphism of S-mephenytoin 4??-hydroxylation in African-Americans
    Timi I. Edeki, Joyce A. Goldstein, Sonia M. F. de Morais · 1996 · Pharmacogenetics
46. Ticlopidine decreases the in vivo activity of CYP2C19 as measured by omeprazole metabolism
    Tomonori Tateishi, Toshio Kumai, Minoru Watanabe · 1999 · British Journal of Clinical Pharmacology
47. Population Pharmacokinetics of Phenytoin in Japanese Patients with Epilepsy: Analysis with a Dose-Dependent Clearance Model.
    Atsuko ODANI, Yukiya Hashimoto, 和伸 高柳 · 1996 · Biological and Pharmaceutical Bulletin
48. Pharmacokinetic Drug Interactions with Phenytoin (Part II)
    Roger L. Nation, Allan M. Evans, Robert W. Milne · 1990 · Clinical Pharmacokinetics
49. Interaction between phenytoin and imipramine.
    Emilio Perucca, A. Richens · 1977 · British Journal of Clinical Pharmacology
50. A Study of the Interaction Between Omeprazole and Phenytoin in Epileptic Patients
    Tommy Andersson, Per-Olof Lagerström, Peter Unge · 1990 · Therapeutic Drug Monitoring
51. Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies*
    Maciej P. Nowak, Edward M. Sellers, Rachel Fynvola Tyndale · 1998 · Clinical Pharmacology & Therapeutics
52. Intrinsic Efficacy of Proguanil against Falciparum and Vivax Malaria Independent of the Metabolite Cycloguanil
    Akira Kaneko, Yngve Bergqvist, Miho Takechi, Morris Kalkoa, Osamu Kaneko, Takatoshi Kobayakawa, Takashi Ishizaki, Anders Björkman · 1999 · The Journal of Infectious Diseases
53. Cobalamin deficiency with megaloblastic anaemia in one patient under long‐term omeprazole therapy
    Abdelouahab Bellou, Isabelle Aimone‐Gastin, Jean-Dominique de Korwin, Jean–Pierre Bronowicki, Anne Moneret-Vautrin, J. P. Nicolas, Marc‐André Bigard, Jean‐Louis Guéant · 1996 · Journal of Internal Medicine
54. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations
    Sompon Wanwimolruk, S. Bhawan, Peter F. Coville, S. C. W. Chalcroft · 1998 · European Journal of Clinical Pharmacology
55. Human CYP2C-mediated stereoselective phenytoin hydroxylation in Japanese: difference in chiral preference of CYP2C9 and CYP2C19
    Toshio Yasumori, Laishun Chen, Qinghua Li · 1999 · Biochemical Pharmacology
56. Steady-State Plasma Concentrations of Imipramine and Desipramine in Relation to S-Mephenytoin 4'-Hydroxylation Status in Japanese Depressive Patients
    Eriko Koyama, Takeshi Tanaka, Kan Chiba · 1996 · Journal of Clinical Psychopharmacology
57. Evidence for the effect of gender on activity of (S)-mephenytoin 4???-hydroxylase (CYP2C19) in a Chinese population
    Zhenhua Xu, Song‐Lin Huang, Zhousheng Xiao · 1997 · Pharmacogenetics
58. Metabolic disposition of imipramine in oriental subjects: relation to metoprolol alpha-hydroxylation and S-mephenytoin 4'-hydroxylation phenotypes.
    Eriko Koyama, Dong‐Ryul Sohn, S. G. Shin · 1994 · Journal of Pharmacology and Experimental Therapeutics
59. Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians
    T. Inaba, M Jurima, Masayuki Nakano · 1984 · Clinical Pharmacology & Therapeutics
60. Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole
    Alan B.R. Thomson · 2000 · Current Gastroenterology Reports
61. Stereoselective disposition of hexobarbital and its metabolites
    Adedayo B. Adedoyin, C. Prakash, D. O??Shea · 1994 · Pharmacogenetics
62. Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient
    Takahisa Furuta · 2000 · Clinical Pharmacology & Therapeutics
63. The role of S‐mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides.
    JD Wright, Nuala Ann Helsby, Stephen Andrew Ward · 1995 · British Journal of Clinical Pharmacology
64. Genotype analysis of the CYP2C19 gene in the Japanese population
    Yutaka Tsuneoka, Kouji Fukushima, Yoshinori Matsuo · 1996 · Life Sciences
65. Effect of CYP2C19 polymorphism on serum levels of vitamin B12 in patients on long‐term omeprazole treatment
    SAGAR, JANCZEWSKA, �. Ljungdahl, Bertilsson, SEENSALU · 1999 · Alimentary Pharmacology & Therapeutics
66. Fatality Associated With Combined Fluoxetine-Amitriptyline Therapy
    Bryan Baker · 1997 · JAMA
67. Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark.
    Kim Brøsen, Erik Skjelbo, Helga Flachs · 1993 · British Journal of Clinical Pharmacology
68. RNA molecules containing exons originating from different members of the cytochrome P450 2C gene subfamily (CYP2C) in human epidermis and liver
    Peter G. Zaphiropoulos · 1999 · Nucleic Acids Research
69. Elevation of steady-state diazepam levels by cimetidine
    Ulrich E. Klotz, Ingrid W. Reimann · 1981 · Clinical Pharmacology & Therapeutics
70. Omeprazole and CYP2C19 polymorphism: effects of long‐term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders
    M. Sagar, Leif Bertilsson, Mats Stridsberg, A. Kjellin, Sven Mårdh, Rein Seensalu · 2000 · Alimentary Pharmacology & Therapeutics
71. Family studies of mephenytoin hydroxylation deficiency.
    T. Inaba, M Jurima, WERNER KALOW · 1986 · PubMed
72. The Role of CYP2C in the In Vitro Bioactivation of the Contraceptive Steroid Desogestrel
    Daniela M. Gentile, Carole Verhoeven, Tsutomu Shimada · 1998 · Journal of Pharmacology and Experimental Therapeutics
73. Diazepam–omeprazole inhibition interaction: an in vitro investigation using human liver microsomes
    Katayoun Zomorodi, J. Brian Houston · 1996 · British Journal of Clinical Pharmacology
74. Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations but not in Chinese populations?
    Leif Bertilsson, WERNER KALOW · 1993 · Clinical Pharmacology & Therapeutics
75. Flunitrazepam oxidative metabolism in human liver microsomes: involvement of CYP2C19 and CYP3A4
    Janet K. Coller, Andrew Alexander Somogyi, Felix Bochner · 1999 · Xenobiotica
76. Pharmacokinetic Fluvoxamine - Clomipramine Interaction with Favorable Therapeutic Consequences in Therapy-resistant Depressive Patient
    Philippe Conus, Guido Bondolfi, Chin B. Eap · 1996 · Pharmacopsychiatry
77. Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects
    Edoardo Spina, Angela Avenoso, Giuseppe Maurizio Campo · 1997 · British Journal of Clinical Pharmacology
78. S-mephenytoin 4-hydroxylation in older Americans
    Bruce G. Pollock, J M Perel, Margaret A. Kirshner · 1991 · European Journal of Clinical Pharmacology
79. Age‐dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin.
    DA Smith, MH Chandler, Steven I. Shedlofsky · 1991 · British Journal of Clinical Pharmacology
80. The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype
    JIE WAN, HUI XIA, Nan He · 1996 · British Journal of Clinical Pharmacology
81. The importance of substrate concentration in determining cytochromes P450 therapeutically relevant in vivo
    Ryuichi Kato, Yasushi Yamazoe · 1994 · Pharmacogenetics
82. Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment.
    Karl Ludwig Rost, Jürgen Brockmöller, Friederike Esdorn · 1995 · PubMed
83. The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype
    JIE WAN, HUI XIA, Nan He · 1996 · British Journal of Clinical Pharmacology
84. Stereoselective 4′‐hydroxylation of phenytoin: relationship to (S)‐mephenytoin polymorphism in Japanese
    Ichiro Ieiri, Kohsuke Mamiya, Akinori Urae et al. · 1997 · British Journal of Clinical Pharmacology
85. CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population
    Mallé Jurima‐Romet, Joyce A. Goldstein, Michael J. LeBelle · 1996 · Pharmacogenetics
86. Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by Atrium®, a fixed combination preparation containing phenobarbital, febarbamate and difebarbamate
    Yves Horsmans, Dominique Lannes, Dominique Pessayre, Dominique G. Larrey · 1994 · Journal of Hepatology
87. Stereoselectivity of differential routes of drug metabolism: the fate of the enantiomers of [14C]mephenytoin in the dog.
    Adrian Kupfer, Johannes Bircher · 1979 · Journal of Pharmacology and Experimental Therapeutics
88. Stereospecific analysis of omeprazole supports artemisinin as a potent inducer of CYP2C19
    Kazuo Mihara, Ulrika S.H. Svensson, Gunnel Tybring · 1999 · Fundamental and Clinical Pharmacology
89. Effect of Sertraline on the Pharmacokinetics and Protein Binding of Diazepam in Healthy Volunteers
    Mark Gardner, Barbara A. Baris, Keith D. Wilner, Sheldon Preskorn · 1997 · Clinical Pharmacokinetics
90. Genetic polymorphism of the hepatic cytochrome P450 2C19 in North Indian subjects*
    Jatinder Kaur Lamba, Radha Krishan Dhiman, Krishan Kumar Kohli · 1998 · Clinical Pharmacology & Therapeutics
91. Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.
    A Drohse, Lise Bathum, Kim Brøsen · 1989 · British Journal of Clinical Pharmacology
92. The steady-state pharmacokinetics of phenytoin (Dilantin) and topiramate (Topamax) in epileptic patients on monotherapy and during combination therapy
    L.G. Gisclon · 1994 · Epilepsia
93. Pharmacokinetic Optimisation of the Treatment of Psychosis
    A. E. Balant-Gorgia, Luc P. Balant, A. Andreoli · 1993 · Clinical Pharmacokinetics
94. Genotype analysis of the CYP2C19 gene in HCV-seropositive patients with cirrhosis and hepatocellular carcinoma
    Tommy Chau, Shigeto MURAKAMI, Bumpei Kawai · 2000 · Life Sciences
95. CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system
    Gary A. Ford, Susan M. Wood, Ann K. Daly · 2000 · British Journal of Clinical Pharmacology
96. Dapsone N-acetylation, metoprolol α-hydroxylation, and S-mephenytoin 4-hydroxylation polymorphisms in an Indonesian population: A cocktail and extended phenotyping assessment trial
    Rianto Setiabudy, Meizoh Kusaka, Kan Chiba · 1994 · Clinical Pharmacology & Therapeutics
97. Stereoselective metabolism and pharmacogenetic control of 5-phenyl-5-ethylhydantoin (nirvanol) in humans.
    Adrian Kupfer, Rashmi V. Patwardhan, Stephen Andrew Ward · 1984 · Journal of Pharmacology and Experimental Therapeutics
98. Genetic polymorphism of S-mephenytoin 4'-hydroxylation.
    H I Daniel, Edeki Ti · 1996 · PubMed
99. Four-week treatment with omeprazole increases the metabolism of caffeine.
    J.‐B. Nousbaum, Francois Berthou, D Carlhant · 1994 · PubMed
100. Mephenytoin hydroxylation in the Cuna Amerindians of Panama.
     T. Inaba, LF Jorge, TD Arias · 1988 · British Journal of Clinical Pharmacology
101. Pharmacogenetic characteristics of the eosinophilia-myalgia syndrome
     David Alastair Flockhart, Daniel Joseph Clauw, Elaine T. Buchert, Jan Hewett, Raymond L. Woosley · 1994 · Clinical Pharmacology & Therapeutics
102. Allele frequency of CYP2C19 in a Portuguese population
     Jorge Lira Ruas, Maria Celeste Lechner · 1997 · Pharmacogenetics
103. Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment
     Karl Ludwig Rost, Jürgen Brockmöller, Friederike Esdorn · 1995 · Journal of Hepatology
104. Imipramine demethylation in vivo: Impact of CYP1A2, CYP2C19, and CYP3A4*
     Hanne Madsen, Birgitte Buur Rasmussen, Kim Brøsen · 1997 · Clinical Pharmacology & Therapeutics
105. P-Hydroxylation of Phenobarbital: Relationship to (s)-Mephenytoin Hydroxylation (CYP2C19) Polymorphism
     Atsuko Hadama, Ichiro Ieiri, Toshihiro Morita et al. · 2001 · Therapeutic Drug Monitoring
106. Evaluation of a Potential Enantioselective Interaction Between Ticlopidine and Warfarin in Chronically Anticoagulated Patients
     Barry E. Gidal, Christine A. Sorkness, Kelly A. McGill · 1995 · Therapeutic Drug Monitoring
107. Potential Pharmacokinetic Interaction between Felbamate and Phenobarbital
     Barry E. Gidal, Mary L. Zupanc · 1994 · Annals of Pharmacotherapy
108. Concurrent use of more than one major psychotropic drug (polypsychopharmacy) in out‐patients—a prescription database study.
     J.-U. Rosholm, Jesper Hallas, LF Gram · 1994 · British Journal of Clinical Pharmacology
109. The genetic defect of mephenytoin hydroxylation
     WERNER KALOW · 1986 · Xenobiotica
110. Effects of ketoconazole on the polymorphic 4‐hydroxylations of S‐ mephenytoin and debrisoquine.
     JO Atiba, Terrence F. Blaschke, G R Wilkinson · 1989 · British Journal of Clinical Pharmacology
111. Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of development of the “serotonin syndrome”*
     Jasper Dingemanse, Andreas Wallnöfer, Ronald Gieschke · 1998 · Clinical Pharmacology & Therapeutics
112. Proguanil polymorphism does not affect the antimalarial activity of proguanil combined with atovaquone in vitro
     Michael D. Edstein, Anthony E. T. Yeo, Dennis E. Kyle · 1996 · Transactions of the Royal Society of Tropical Medicine and Hygiene
113. The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio). A population study.
     Erik Skjelbo, L. F. Gram, Kim Brøsen · 1993 · PubMed
114. Cimetidine interaction with amitriptyline
     Stephen H. Curry, C. Lindsay DeVane, M. Michael Wolfe · 1985 · European Journal of Clinical Pharmacology
115. Biliary excretion of intravenous [14C] omeprazole in humans
     Tore Lind, Tommy Andersson, Inger Skånberg · 1987 · Clinical Pharmacology & Therapeutics
116. Debrisoquine and mephenytoin oxidation in Sinhalese: a population study.
     K Weerasuriya, RL Jayakody, CA Smith · 1994 · British Journal of Clinical Pharmacology
117. Role of CYP2C19 in stereoselective hydroxylation of mephobarbital by human liver microsomes.
     Kaoru Kobayashi, Mari Kogo, Masayoshi Tani · 2001 · PubMed
118. Elevation of plasma phenytoin by viloxazine in epileptic patients: a clinically significant drug interaction.
     F Pisani, A. Fazio, Catalina Julia Artesi · 1992 · Journal of Neurology Neurosurgery & Psychiatry
119. Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide
     Marie‐Paule Schoerlin, Michael Mayersohn, B. Hoevels · 1991 · Clinical Pharmacology & Therapeutics
120. Acute Phenytoin Toxicity Followed by Seizure Breakthrough From a Ticlopidine-Phenytoin Interaction
     Michael Privitera, Timothy E. Welty · 1996 · Archives of Neurology
121. The relationship between phenytoin pharmacokinetics and the CYP2C19 genotype in Japanese epileptic patients.
     Masao Watanabe, K Iwahashi, Toshiaki Kugoh · 1998 · PubMed
122. Effect of omeprazole on the pharmacokinetics of sustained-release carbamazepine in healthy male volunteers
     R.K. Dixit, Chawla, A.B., Narinder Kumar · 2001 · Methods and Findings in Experimental and Clinical Pharmacology
123. CYP2C19 genotypes and omeprazole metabolism after single and repeated dosing when combined with clarithromycin
     Qian Zhou, Isamu Yamamoto, Tsuyoshi Fukuda · 1999 · European Journal of Clinical Pharmacology
124. Frequency of S-mephenytoin hydroxylation deficiency in 373 spanish subjects compared to other Caucasian populations
     Jesús Reviriego, Leif Bertilsson, Juan Antonio Carrillo · 1993 · European Journal of Clinical Pharmacology
125. Diazepam-Cimetidine Drug Interaction
     Richard L. Ruffalo, John F. Thompson, Jack L. Segal · 1981 · Southern Medical Journal
126. Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers
     Jung Min Ko, In‐Jin Jang, J SHIN · 1999 · Clinical Pharmacology & Therapeutics
127. Ticlopidine inhibits phenytoin clearance
     S DONAHUE, D FLOCKHART, D ABERNETHY · 1999 · Clinical Pharmacology & Therapeutics
128. No Interaction of Diazepam on Amitriptyline Disposition in Depressed Patients
     Koichi Otani, Conny Nordin · 1987 · Therapeutic Drug Monitoring
129. Theophylline steady state pharmacokinetics is not altered by omeprazole
     Anne Marie Taburet, Jean Genève, Muriel Bocquentin · 1992 · European Journal of Clinical Pharmacology
130. Sparteine and mephenytoin oxidation: Genetic polymorphisms in East and West Greenland
     Knud Clasen, Laila Madsen, Kim Brøsen · 1991 · Clinical Pharmacology & Therapeutics
131. Debrisoquine and S -mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia
     Toomas Marandi, Marja­‐Liisa Dahl, Lembit Rägo · 1997 · European Journal of Clinical Pharmacology
132. Mephenytoin disposition and serum bile acids as indices of hepatic function in chronic viral hepatitis*
     Patricia A. Arns, Adedayo B. Adedoyin, A DIBISCEGLIE · 1997 · Clinical Pharmacology & Therapeutics
133. Comparison of chloroguanide and mephenytoin for the in vivo assessment of genetically determined CYP2C19 activity in humans*
     Chohreh Partovian, Évelyne Jacqz-Aigrain, A Keundjian · 1995 · Clinical Pharmacology & Therapeutics
134. Proton pump inhibitory therapy: then and now.
     Wolfgang Schepp · 1997 · PubMed
135. Induction of imipramine metabolism following barbiturate administration [proceedings]
     DS Hewick, RG Sparks, IH Stevenson · 1977 · British Journal of Clinical Pharmacology
136. Influence of corticosteroid on hexobarbital and tolbutamide disposition
     Douwe D. Breimer, Walter Zilly, Erik Arne Richter · 1978 · Clinical Pharmacology & Therapeutics
137. Relationship between mephenytoin oxidation polymorphism and phenytoin, methylphenytoin and phenobarbitone hydroxylation assessed in a phenotyped panel of healthy subjects.
     J.H.M. Schellens, JH van der Wart, Douwe D. Breimer · 1990 · British Journal of Clinical Pharmacology
138. Debrisoquin and S‐Mephenytoin Hydroxylation Phenotypes and CYP2D6 Genotypes in an Estonian Population
     Toomas Marandi, Marja­‐Liisa Dahl, Raul Allan Kiivet · 1996 · Pharmacology & Toxicology
139. Lung cancer risk in relation to mephenytoin hydroxylation activity
     Simone Benhamou, Christine Bouchardy, Pierre Dayer · 1997 · Pharmacogenetics
140. S‐mephenytoin, sparteine and debrisoquine oxidation: genetic polymorphisms in a Turkish population.
     NE Basci, Kim Brøsen, Atilla Bozkurt · 1994 · British Journal of Clinical Pharmacology
141. The hydroxylation of omeprazole correlates with S -mephenytoin and proguanil metabolism
     Selim Kortunay, N. E. Başcı, Atilla Bozkurt · 1997 · European Journal of Clinical Pharmacology
142. Polymorphisms in oxidative drug metabolism: relationship to food preference.
     M R Britto, HE McKean, GG Bruckner · 1991 · British Journal of Clinical Pharmacology
143. Frequency of impaired mephenytoin 4′‐hydroxylation in an Indian population [letter]
     BS Doshi, Kulkarni Rd, Chauhan Bl · 1990 · British Journal of Clinical Pharmacology
144. S-Mephenytoin hydroxylation phenotypes in a Jordanian population*
     Hakam F. Hadidi, Yacoub M. Irshaid, Raymond L. Woosley · 1995 · Clinical Pharmacology & Therapeutics
145. Cimetidine-Imipramine Interaction: Case Report and Comments
     Peter A. Shapiro · 1984 · American Journal of Psychiatry
146. Imipramine metabolism in relation to the sparteine oxidation polymorphism - a family study
     Hanne Madsen, T S Hansen, Kim Brøsen · 1996 · Pharmacogenetics
147. Selective and Potent Inhibition of Human CYP2C19 Activity by a Conformationally Targeted Antipeptide Antibody
     Timothy Schulz-Utermoehl, Richard J. Mountfield, Kjeld Madsen · 2000 · Drug Metabolism and Disposition
148. Diazepam Treatment Does Not Influence the Debrisoquine or Mephenytoin Hydroxylation Phenotyping Tests
     Eduardo Spina, Anna Lucia Buemi, DREmilio Sanz · 1989 · Therapeutic Drug Monitoring
149. Fluoxetine—Imipramine Interaction
     Iracema Leroi, Magdalena A Walentynowicz · 1996 · The Canadian Journal of Psychiatry
150. Dose dependent induction of CYP1A2 activity by omeprazole (Antra).
     Rost Kl, H. Brösicke, Matthias Scheffler · 1992 · PubMed
151. Possible Interaction Between Imipramine and Butalbital
     Kevin W. Garey, Guy W. Amsden, Celeste A. Johns · 1997 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
152. Cimetidine-imipramine interaction: case report and comments
     1984 · American Journal of Psychiatry
153. Hepatic cytochrome P450 CYP2C activity in psoriasis: studies using proguanil as a probe compound: Investigative reports
     Nuala Ann Helsby · 1998 · Acta Dermato Venereologica
154. Genotype analysis of the CYP2C19 gene in HCV-seropositive patients with cirrhosis and hepatocellular carcinoma
     建雄 鄒 · 2001 · Medical Entomology and Zoology
155. Effects of omeprazole and cimetidine on the urinary metabolic ratio of proguanil in healthy volunteers
     Andrew Alexander Somogyi, HELEN A. REINHARD, Felix Bochner · 1996 · European Journal of Clinical Pharmacology
156. Blue-chip technology
     David Alastair Flockhart, David John Webb · 1998 · The Lancet
157. No correlation between side-chain of propranolol oxidation and S-mephenytoin 4'-hydroxylase activity.
     Hong‐Guang Xie, Zhenhua Xu, Song‐Lin Huang · 1997 · PubMed
158. The Relationship between CYP2Cl9 Genotype and Phenytoin Pharmacokinetics in Japanese Epileptic Patients.
     Masao Watanabe, Kazuhiko Iwahashi, Toshiaki Kugoh · 1996 · てんかん研究